Potentised Black Lead in the Treatment of Polycystic Ovarian Syndrome: An Evidence-Based Case Report

Abstract

Polycystic ovarian syndrome (PCOS) is a common condition among females of the childbearing age group. The exact cause of PCOS is unknown and increased levels of male hormones are believed to cause anovulation. It can cause several long-term complications, including infertility, metabolic disorders and cardiovascular disorders. PCOS is diagnosed based on Rotterdam diagnostic criteria. Globally, the estimated prevalence of PCOS ranges between 5 and 15%. The prevalence in south India is 6%. In this case report, a case of PCOS successfully treated with individualised medicine Graphites is given. The improvement is evident from symptomatic relief and decreased ovarian volume on ultrasonography abdomen and pelvis after 9 months of homeopathic treatment. Subsequently, the patient conceived. Thus, homeopathic medicine was found effective in the treatment of this PCOS case.

Keywords

polycystic ovarian syndrome - Rotterdam criteria - Graphites

Patient Perception

I am happy that my menstrual cycle is regularised and that I have conceived by being on homeopathic medicines which are not typically hormonal treatments. I am happy to get regular menses and pregnancy by homeopathic medicine. I am also glad that I conceived without hormonal treatment.

Declaration of Patient Consent

Informed consent for investigation, as well as for potential future use of patients' data for scientific publications was taken.

Publication History

Article published online:
30 September 2022

• References

• 1 Ndefo UA, Eaton A, Green MR. Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. P&T 2013; 38 (06) 336-355
• 2 Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018; 14 (05) 270-284
• 3 Bani Mohammad M, Majdi Seghinsara A. Polycystic ovary syndrome (PCOS), diagnostic criteria, and AMH. Asian Pacific journal of cancer prevention. Asian Pac J Cancer Prev 2017; 18 (01) 17-21
• 4 Bharathi RV, Swetha S, Neerajaa J. et al. An epidemiological survey: effect of predisposing factors for PCOS in Indian urban and rural population. Middle East Fertil Soc J 2017; 22 (04) 313-316
• 5 Azziz R. Introduction: determinants of polycystic ovary syndrome. Fertil Steril 2016; 106 (01) 4-5
• 6 Welt CK, Gudmundsson JA, Arason G. et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 2006; 91 (12) 4842-4848
• 7 Peigné M, Dewailly D. Long term complications of polycystic ovary syndrome (PCOS). Annales d'endocrinologie 2014; 75 (04) 194-199 Elsevier Masson. PubMed
• 8 Sawant A, Patil S, Shah S. Review on PCOD/PCOS & its treatment in different medicinal systems–allopathy, ayurveda, homeopathy. Sci Jurno 2017; 1 (01) 1-6
• 9 Lamba CD, Gupta VK, van Haselen R. et al. Evaluation of the modified Naranjo criteria for assessing causal attribution of clinical outcome to homeopathic intervention as presented in case reports. Homeopathy 2020; 109 (04) 191-197
• 10 Warren-Ulanch J, Arslanian S. Treatment of PCOS in adolescence. Best Pract Res Clin Endocrinol Metab 2006; 20 (02) 311-330
• 11 Moghetti P, Castello R, Negri C. et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85 (01) 139-146
• 12 Rath P. Management of PCOS through homoeopathy—a case report. Ind J Res Homeopath 2018; 12 (02) 95-100
• 13 Lamba CD, Oberai P, Manchanda RK, Rath P, Bindu PH, Padmanabhan M. Evaluation of homoeopathic treatment in polycystic ovary syndrome: a single-blind, randomised, placebo-controlled pilot study. Indian J Res Homoeopathy 2018; 12: 35-45